Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

welcome you to the Q4 2024 Seed and Farmers Utilities, Inc. Earnings Conference Call. All lines have been placed in view to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the conference over to Chad Pugier. Please go ahead. Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's fourth quarter and full year 2024 financial and operating results. Joining me are Ian Mortimer, Xenon's President and Chief Executive Officer, Dr. Chris Kenney, Xenon's Chief Medical Officer, and Sherry Allen, Xenon's Chief Financial Officer. After completing their prepared remarks today, we will open the call up for your questions. Please be advised that during this call, we will make a number of statements that are forward looking. including statements regarding the timing of and potential results from clinical trials, the potential efficacy, safety profile, future development plan, and current and anticipated indications, addressable market, regulatory success, and commercial potential of our and our partner's product candidate. The efficacy of our clinical trial design, our ability to successfully develop and achieve milestones in our clinical development program, including the anticipated filing of INDs and NDAs, the timing and results of our interactions with regulators, our ability to successfully obtain regulatory approval, anticipated timing of top-line data readout for clinical trials of the Z2 calendar, and our expectation that we'll have sufficient cash to fund operations in 2027. Tod...